Ocular Therapeutix hammered by a PhII failure in dry eye disease — shares tank
Ocular Therapeutix $OCUL has had its ups and downs in the 7 years since it went public. Friday was one of those down days. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
